Status:
COMPLETED
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders
Lead Sponsor:
MinYoung Kim, M.D.
Conditions:
Brain Injury
Cerebral Palsy
Eligibility:
All Genders
19-75 years
Phase:
NA
Brief Summary
This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for pati...
Detailed Description
Current treatments for brain injury or neurodegenerative disorders are palliative rather than curative. Preclinical and some clinical studies suggest that UCB and G-CSF can be used as restorative appr...
Eligibility Criteria
Inclusion
- should be included one of the 4 disorders
- Brain injury: onset duration over 12 months, Age: 19 years or over
- Cerebral palsy: spastic, dyskinetic or ataxic, Age: 19 years or over
- Parkinson's disease: modified Hoehn and Yahr stage 2.5, 3, 4, Age: 30 to 75 years
- ALS: definite of possible ALS, progression during the past 6 months, Age: 19 to 65
Exclusion
- Uncontrolled pulmonary, renal dysfunction at enrollment
- Uncontrolled seizure
- Malignant cancer
- Possibility of hypersensitivity to drugs used in this study
- Contraindication to the study intervention or assessment
- Pregnant or breast feeding women
- Non-compliance with the study visits specified in the protocol
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02236065
Start Date
August 1 2014
End Date
July 1 2016
Last Update
October 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea, 463-712